SML4308
Megestrol acetate
≥98% (HPLC)
别名:
17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione, 6-Dehydro-6-methyl-17α-acetoxyprogesterone, 6-Methyl-17α-acetoxy-4,6-pregnadiene-3,20-dione, Megestryl acetate
一般描述
Potent progesterone receptor (PR) agonist/androgen receptor (AR) antagonist for hormone cancers and cachexia.
Megestrol acetate, a well-absorbed oral synthetic progestogen, targets progesterone receptor (PR) (~130% progesterone affinity), androgen receptor (AR) (~5% metribolone affinity, antiandrogenic), and glucocorticoid receptor (GR) (~30% dexamethasone affinity). This dual action supports its use in hormone-sensitive cancers (breast, endometrial, prostate) by inhibiting proliferation and estrogenic effects, and in prostate cancer via potential 5α reductase inhibition. Clinically, megestrol acetate acts as an antiandrogen and potent appetite stimulant, with an unclear mechanism involving Neuropeptide Y. Megestrol acetate’s efficacy in palliative cancer care and cachexia management, sometimes synergistic with tamoxifen, is tempered by potential GR-related side effects.
Megestrol acetate, a well-absorbed oral synthetic progestogen, targets progesterone receptor (PR) (~130% progesterone affinity), androgen receptor (AR) (~5% metribolone affinity, antiandrogenic), and glucocorticoid receptor (GR) (~30% dexamethasone affinity). This dual action supports its use in hormone-sensitive cancers (breast, endometrial, prostate) by inhibiting proliferation and estrogenic effects, and in prostate cancer via potential 5α reductase inhibition. Clinically, megestrol acetate acts as an antiandrogen and potent appetite stimulant, with an unclear mechanism involving Neuropeptide Y. Megestrol acetate’s efficacy in palliative cancer care and cachexia management, sometimes synergistic with tamoxifen, is tempered by potential GR-related side effects.
法规信息
新产品
此项目有
历史批次信息供参考:
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持